Project #80: Nano-in-microgel long-acting combination drug delivery platform for localized immunomodulation to prevent allogenic islet graft immune rejection in extrahepatic transplantation sites
Project #80 funds research on nano-in-microgel drug delivery systems for localized immunomodulation to prevent immune rejection in islet transplantation, supported by the Diabetes Research Connection.
Funder: Diabetes Research Connection
Due Dates (Anticipated): July 2027 (application open and close, projected)
Funding Amounts: Up to $75,000 per award for one year; graduate students eligible for up to $50,000, postdocs and junior faculty up to $75,000
Summary: Supports early-career researchers developing innovative approaches to improve islet transplantation outcomes for type 1 diabetes by reducing immune rejection.
Key Information: Forecasted grant: all dates are projected; see program page for updates.
Description
This opportunity, funded by the Diabetes Research Connection (DRC), supports early-career scientists working on innovative, early-stage research related to type 1 diabetes (T1D). The specific focus is on projects such as the development of nano-in-microgel drug delivery systems to improve the safety and effectiveness of islet cell transplantation by minimizing immune rejection. The program aims to enable proof-of-concept studies that could position grantees for future, larger-scale funding and ultimately advance the field toward better T1D cures and management.
